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Introduction
Epilepsy is a relatively common neurological disease 
defined by two unprovoked seizures (or one unprovoked 
seizure with the likelihood of more) that were not caused 
by some known and reversible medical condition [1]. It 
affects about 0.5–1% of the population worldwide or abso-
lutely about 50 million of population, around half of them 
(24 millions) diagnosed with active idiopathic epilepsy [2]. 
Approximately 10% of world population will experience a 
seizure at some point during their lifetime [3].The inci-
dence of epilepsy is about 61 per 100000 persons-years and 
was higher in  low/middle-income countries than in high-
income countries, 139.0 vs 48.9 [3]. Epilepsy is still an im-
portant cause of disability (25% of people with epilepsy have 
intellectual disability [4]), mortality, and is surrounded by 
prejudice and stigma – a well-documented barrier to health 
seeking behavior, engagement in care and adherence to 
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Abstract
Background: Drug-resistant epilepsy is the cause of severe disability. Multiple questions remain unanswered both in terms of pathogenesis and therapeutic 
management. For this narrative review, PubMed database and Infomedica library were searched by using “drug-resistance in epilepsy” and “treatment 
of drug-resistant epilepsy” as key words. The following filters were applied: “Clinical Trial”, “Meta-analysis”, “Multicenter Study”, and “Randomized 
Controlled Trial”, covering the period of 01.01.2005–06.01.2021.Several hypotheses have been proposed, i.e., pharmacokinetic, intrinsic severity, gene, 
target, transporter, and neural network hypotheses. Many controlled trials showed different results in terms of seizure control after combined methods 
of therapies. Immunotherapy, palliative epilepsy surgery alone or associated with neurostimulation procedures including vagus nerve, trigeminal nerve, 
or deep brain stimulation may be efficient, however, seizure freedom is not always achieved. Genetic epilepsies might benefit from gene and exosome 
therapy; however, further studies are needed to verify their safety. 
Conclusions: Neuroscience of drug-resistant epilepsy faces many challenges. Inflammatory mediators, biomarkers, and genes might allow the identification 
of new treatment targets, contribute to an earlier diagnosis, and assess the clinical outcomes.
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treatment across a range of health conditions globally [5], 
perceived by cohabiting relatives of people with epilepsy and 
surrounded people. Higher perceived stigma is significantly 
related to generalized seizures, longer disease duration [6], 
and higher perceptions of stigma are associated with worse 
quality of life in people with epilepsy. SUDEP is a life-threat-
ening condition with an estimated incidence of 0.58 to 9.0 
per 1000 persons-years with a 35% of lifetime cumulative 
risk in refractory epilepsy patients [7] that is playing an im-
portant role in the quality of life of these patients. People 
with epilepsy have a higher risk of sudden death, with re-
ported annual incidences of 1 per 1000. For those with un-
controlled epilepsy, the incidence is higher as 1 per 200 [8], 
but the lowest incidence is in children and consists 0–0.2 per 
1000 [9]. The risk of sudden death is greater in women, rep-
resenting 1.45 per 1000 than in men 0.98 per 1000 [10]. The 
epilepsy treatment with antiepileptic drugs has limited ef-
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fectiveness. In case of correct diagnosis, 70% of patients with 
epilepsy are drug sensitive and seizure free, 50% of them af-
ter initial monotherapy [11], 10% in context of alternative 
monotherapy and 10% with first add-on or polytherapy. The 
remaining 30% are drug resistant. These data may fluctuate 
with 25% range of drug-resistance [12].
The modern definition of drug resistance
The concept drug-resistant epilepsy means pharmacore-
sistant, drug resistant, refractory or medically intractable ep-
ilepsy [13]. The definition evaluated during the last years as: 
a) seizures which have not been completely controlled with 
AEDs 1 year after onset despite accurate diagnosis and care-
fully monitored treatment [14]; b) seizures of sufficient fre-
quency and severity after 2 years of AED treatment [15]; c) 
the patient is not seizure free after 1 year treatment with 2–3 
AED [16]. The ILAE consensus concerning definition was 
obtained in 2009 and it is: failure of adequate trials of two 
tolerated and appropriately chosen and used AEDs (whether 
as monotherapies or in combination) to achieve sustained 
seizure freedom [13]. Discussing about pharmacoresistant 
epilepsy is very important to rule out cases of nonadherence 
in epilepsy and cases of pseudorefractory epilepsy [17]The 
approach of patient with pharmacoresistant epilepsy is dif-
ficult and the first step would be the diagnosis reconsidera-
tion. The surgery is the superior option in treatment of these 
patients, but among the 30% of patients with confirmed di-
agnosis of pharmacoresistant epilepsy only 10–15% become 
candidates for epilepsy surgery [18]. 
Mechanisms of drug resistance
Nowadays understanding the multifactorial mechanisms 
underlying drug-resistant epilepsy has the potential to 
contribute to more effective development of treatment 
options for patients with epilepsy. The combination of 
multiple mechanisms expressed in each individual patient 
represents the most popular hypothesis. A key limitation of 
the entire research is the difficulty of demonstrating whether 
the changes associated with drug-resistant epilepsy are an 
epiphenomenon of epileptogenesis [19].
Intrinsic severity hypothesis. Rogawski and Johnson 
proposed the hypothesis that the resistance of antiepileptic 
drugs is not due to specific drug resistance factors, but 
due to the degree of severity of epilepsy that is directly 
related to the response to treatment. This “intrinsic severity 
hypothesis” was later updated by Rogawski, who postulates 
that drug resistance is an inherent property of epilepsy 
that is directly related to the severity of the disease. The 
increased frequency or density of seizures that precede the 
onset of antiepileptic therapy is the most important factor 
associated with a reduced chance of long-term remission of 
the disease [20]. Although the high frequency of seizures is 
a predictor of drug resistance, but it is clearly not the only 
one. The intrinsic severity hypothesis says that common 
neurobiological factors contribute to both the severity of 
epilepsy and pharmaceutical co-resistance. Other features 
of the severity of the pathological condition, such as the 
extent of structural damage or behavioral phenotype, are 
also predictors of resistance to antiepileptic drugs. Although 
the intrinsic severity hypothesis seems biologically possible, 
it was not applied to disease with a fluctuating or evolving 
pattern of resistance. In addition, there is very limited 
evidence to support a direct link between the severity of 
epilepsy and response to treatment [21]. In this regard, data 
from studies supporting the hypothesis of intrinsic severity 
suggest that the high frequency of pre-treatment seizures is 
an important predisposing factor for refractory epilepsy [22]. 
A similar conclusion was drawn from a study on children 
diagnosed with epilepsy, which showed that administration 
of anticonvulsant therapy during the period of first ten 
seizures had no aggravating or early remission effect [23]. In 
another randomized study of 1847 patients with epilepsy, the 
authors compared the effectiveness of immediate treatment 
with that of the delayed treatment and found that immediate 
treatment was associated with reduced seizure frequency in 
the first 1–2 years, but long-term remission rates did have 
no difference between the two groups. Therefore, it has 
been suggested that the theory of intrinsic severity does 
not sufficiently explain the mechanism of drug resistance in 
epilepsy [21].
Target hypothesis. Among the various mechanisms of 
drug resistance that have been proposed, the target hypoth-
esis postulates that acquired (epilepsy-induced) alterations 
to the structure and/or functionality of brain targets of anti-
seizure drugs (ASDs) lead to a reduction in their sensitivity 
to treatment and thus lead to refractoriness [24]. To exhibit 
antiseizure activity, a drug must act on one or more target 
molecules in the brain, and these targets include voltage-
dependent ion channels, neurotransmitter receptors, and 
transporters or metabolic enzymes involved in the release, 
uptake, and metabolism of neurotransmitters [25]. 
The target hypothesis is primarily based on studies with 
carbamazepine on voltage-gated sodium channels in hippo-
campal neurons (CA1 and dentate granule cells). Remy et al. 
[26] showed that the use dependent block of voltage-depen-
dent Na+ channels of dentate granule cells by carbamazepine 
is completely lost in patients with carbamazepine-resistant 
temporal lobe epilepsy (TLE), and the fast recovery from 
inactivation of the fast Na+ current was carbamazepine-
insensitive in pharmacoresistant patients [27]. Also, the au-
thors suggested that a loss of Na+ channel drug sensitivity 
could explain the development of drug-resistant epilepsy 
(DRE). In another study, Remy et al. [28] demonstrated that 
the effects of phenytoin on fast recovery from inactivation 
of Na+ channels of hippocampal granule neurons were sig-
nificantly reduced, though not as pronounced as observed 
with carbamazepine, and that lamotrigine slowed the time 
course of recovery from fast inactivation. Thus, these results 
suggested that target mechanisms of drug resistance are cell 
type- and ASD-specific. Newly, Doeser et al. [29] reported 
that eslicarbazepine may possess advantages over conven-
tional Na+ channel modulators, because it maintained activ-
ity in chronically epileptic tissue. One possibility for altered 
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sensitivity of Na+ channels in CA1 or dentate granule cells 
in epileptic tissue is that the subunit composition of these 
channels is altered, resulting in channels with lower ASD 
sensitivity [24]. 
Other drug targets, such as GABAA receptors, may be 
altered in patients and animal models with intractable 
epilepsy [27]. Profound alterations in GABAA receptor 
subtype expression have also been reported in adult 
patients with ASD-resistant TLE and pediatric epilepsy 
patients undergoing epilepsy surgery. Brooks-Kayal et al. 
[30], using the rat pilocarpine model of TLE, demonstrated 
that expression of GABAA receptor subunit mRNAs is 
substantially altered in hippocampal dentate granule 
cells of pilocarpine treated rats versus controls. These 
changes in GABAA receptor subunit expression correlated 
with profound alterations in receptor function and 
pharmacology. In addition to the enhanced zinc sensitivity, 
GABAA receptors from the epileptic hippocampus lose 
their sensitivity to augmentation by the benzodiazepine 
site modulator zolpidem. However, none of these studies 
examined whether ASD-resistant epileptic rats differ 
from responsive rats in these changes in GABAA receptor 
function [27].
Although the target hypothesis is a biologically plausible 
theory to explain drug resistance, the fact that most drug-
resistant patients are resistant to several ASDs acting on 
different therapeutic targets undermines the general utility 
of the target hypothesis and instead supports the existence 
of a mechanism nonspecific to individual ASDs [31]. 
Transporter hypothesis. The transporter hypothesis is 
based on two assumptions: (1) overexpression of efflux 
transporters correlates with pharmacoresistance in epilepsy 
and (2) antiepileptic drugs (AEDs) are subject to active 
transport by efflux transporters [31]. 
Overexpression of efflux transporters at the blood–brain 
barrier is discussed as one factor that might limit brain 
penetration and efficacy of AEDs. The best understood 
efflux transporters are members of the ABC (ATP-binding 
cassette) superfamily subfamilies B, C, and G, specifically 
P-glycoprotein (ABCB1 or MDR1), the multidrug resistance-
associated proteins (MRP1, ABCC1; MRP2, ABCC2), and 
breast cancer resistance protein (BCRP, ABCG2) [31]. 
P-glycoprotein (P-gp), also known as MDR1 or ATP-
binding cassette subfamily B member 1 (ABCB1), actively 
exports hydrophobic and amphipathic molecules from the 
inside of cells or membranes to the outside, as a critical 
defense mechanism. Its overexpression in epileptogenic 
brain tissue in patients with refractory epilepsy has been 
documented in numerous studies. For the first time 
overexpression of  MDR1  mRNA was demonstrated in 
11 out of 19 resected brain specimens from patients 
with refractory focal epilepsy. P-gp overexpression was 
also detected in astrocytes and/or dysplastic neurons 
in common pathological causes of refractory epilepsy, 
including dysembryoplastic neuroepithelial tumors (DNT), 
hippocampal sclerosis (HS), and focal cortical dysplasia 
(FCD) [32].
The overexpression of a multidrug resistance-associated 
protein (MRP1) in astrocytes and/or dysplastic neurons in 
HS, DNT, and FCD has also been described [32]. The results 
confirm that MRP1 protein expression levels in astrocytes 
and neurons from brain tissue of epilepsy patients are 
significantly increased compared to brain tissue from 
healthy individuals, while endothelial MRP1 expression 
did not differ between the two [33]. It was reported 
increased  MRP2  and  MRP5  mRNA levels in endothelial 
cells isolated from epileptic brain tissue of patients with 
refractory epilepsy compared to control endothelial cells 
from human umbilical vein and aneurysm domes. Aronica 
et al. [34] reported MRP2 protein overexpression in 
endothelial cells and astrocytes in HS tissue specimens of 
adult patients with temporal lobe epilepsy (TLE). 
Similar to P-gp, BCRP (breast cancer resistance 
protein) transports a wide variety of substrates, and its 
tissue distribution contributes to its important roles in 
restricting absorption and facilitating elimination of drugs 
and xenobiotics, but due to the lack of evidence on BCRP 
overexpression in human epileptic brain tissue, BCRP is 
unlikely a major player in AED resistance as proposed by 
the transporter hypothesis [31].
Although increased mRNA and protein expression levels 
of P-gp and MRPs have been demonstrated in resected brain 
tissue from patients with AED-resistant epilepsy, previous 
studies did not include proper controls, as it is generally 
difficult to obtain brain tissue from either patient with 
drug-responsive epilepsy or from healthy subjects without 
brain disease. Therefore, it is still unclear if overexpression 
of efflux transporters correlates with and potentially causes 
AED resistance, or if it is an epiphenomenon of epilepsy in 
humans that is unrelated to AED resistance [35].
Conclusive evidence that AEDs are transported by efflux 
transporters at therapeutic concentrations is considered 
the weak link in the transporter hypothesis. Early studies 
suggested that several AEDs may be substrates for P-gp 
and/or MRPs. Researchers who attempted to identify 
AEDs as substrates of P-gp, MRPs, and/or BCRP mainly 
used three approaches: transporter-overexpressing cell 
lines, transporter inhibition in cell lines and/or in animals, 
and transporter gene knockout mice [36]. Each of these 
approaches has its own strengths and weaknesses. For 
example, transporter-overexpressing cell lines only allow in 
vitro  analysis. Transporter inhibitors may lack specificity 
and interact with more than one transporter, and knockout 
mice may show potential compensatory upregulation of 
other transporters, which may complicate the situation. 
Therefore, all three approaches may need to be used together 
in one thorough study to obtain conclusive data [32]. In 
addition, compared to chemotherapeutic drugs that are 
usually high-affinity substrates for P-gp and MRPs, AEDs 
are weak substrates for the efflux transporters and more 
easily cross the blood-brain barrier under physiological 
conditions [37].
AED Transport by P-gp. P-glycoprotein transports 
primarily hydrophobic and amphipathic compounds [7]. 
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Most AEDs are planar lipophilic molecules, and therefore, 
theoretically many AEDs should be P-gp substrates [19]. 
The first report of P-gp-mediated transport of an AED came 
from Tishler et al. [38], who reported lower steady-state 
intracellular phenytoin concentrations in MDR1-expressing 
neuroectodermal cells as compared to MDR1-negative cells. 
Phenobarbital, lamotrigine, felbamate, and oxcarbazepine 
were shown to be transported by P-gp in rat brain 
microdialysis studies using verapamil as a P-gp inhibitor 
[39]. Owen et al. [40] concluded that carbamazepine 
was not a substrate for P-gp. In contrast, other studies, 
supported that P-gp transports carbamazepine. Data from 
another microdialysis study in rat suggest that P-gp does 
not transport levetiracetam and valproic acid [41]. 
Luna-Tortós et al. [42] pointed out that conventional 
bidirectional transport assays may not be suitable to iden-
tify AEDs as P-gp substrates due to the highly permeable 
nature of most AEDs. Using a modified transport assay 
(concentration equilibrium transport assay; CETA) which 
allows evaluating active transport separately from passive 
permeability, it was detected P-gp transport of phenytoin, 
phenobarbital, lamotrigine, levetiracetam, and topiramate, 
but not carbamazepine in MDR1-transfected LLC-PK1 
cells. Zhang et al. [36] used both the cell monolayer bidi-
rectional assay and CETA in MDR1-transfected MDCKII 
and LLC-PK1 cells to test if phenytoin, phenobarbital, or 
ethosuximide were transported by P-gp. Results from the 
CETA experiments suggested concentration-dependent 
P-gp transport of phenytoin in both MDCKII-MDR1 and 
LLC-PK1-MDR1 cells and transport of phenobarbital only 
in MDCKII-MDR1 cells.
The only clinical evidence linking overexpression of 
blood-brain barrier P-gp to reduced AED brain levels came 
from a pilot study by Marchi et al. [43], who demonstrated an 
inverse correlation between the brain-plasma concentration 
ratio of the major active metabolite of oxcarbazepine, 
10,11-dihydro-10-hydroxy-5H-dibenzo(b,f )azepine-5-
carboxamide(10,11-dihydro-10-hydroxycarbama-zepine), 
and the  MDR1  mRNA brain expression levels in resected 
epileptic tissue from patients with refractory epilepsy.
Since different models yield different results, both  in 
vivo  and  in vitro  data seem to be needed to identify 
which AEDs are substrates for which transporter [31]. In 
this regard, by combining the available evidence, Zhang 
et al. [35] suggested that lamotrigine, oxcarbazepine, 
phenobarbital, and phenytoin are considered definite P-gp 
substrates, because P-gp-mediated transport of these AEDs 
has been supported by both in vivo and in vitro evidence.
AED Transport by MRPs. MRPs transport neutral 
organic drugs and amphiphilic organic anions including 
drugs conjugated to glutathione, sulfate, glucuronate, and 
phosphate. Thus, it is possible that MRPs transport a number 
of AEDs and/or their metabolites and limit their access to 
the brain. Phenytoin transport by MRP1 and/or MRP2 was 
shown in vivo in normal rats using brain microdialysis with 
the MRP1/2 inhibitor probenecid. Carbamazepine and 
oxcarbazepine were shown to be substrates of MRP1 and/
or MRP2 in microdialysis  in vivo  studies with probenecid 
[39]. Valproic acid was the first AED found to be a substrate 
for MRPs in brain endothelial cells. Potschka et al. [44] 
showed that levetiracetam was not transported by MRP1/2. 
Baltes et al. [45] conducted bidirectional transport assays 
in monolayers of MRP2-transfected MDCKII kidney cells, 
and none of the AEDs tested (phenytoin, levetiracetam, 
carbamazepine) was found to be transported by MRP2. 
Using CETA in MDCKII kidney cells transfected with 
human MRP1, MRP2, or MRP5, Luna-Tortós et al. reported 
that none of the AEDs tested (topiramate, valproate, 
carbamazepine, phenytoin, levetiracetam, lamotrigine, and 
phenobarbital) was transported by any of those MRPs [46]. 
In vivo  studies may be needed to confirm the findings 
from  in vitro  experiments, but few clinical studies have 
focused on studying the relationship between AEDs and 
MRPs.
AED Transport by BCRP. Substrate specificity of BCRP 
significantly overlaps with that of P-gp. However, the role of 
BCRP in AED resistance is less well studied in comparison 
to P-gp or the MRPs [31]. Using BCRP-transfected MDCKII 
cells, Cerveny et al. [47] reported that none of the tested 
AEDs (phenobarbital, phenytoin, ethosuximide, primidone, 
valproate, carbamazepine, clonazepam, and lamotrigine) 
was transported by BCRP. However, Nakanishi et al. [48] 
reported that the brain-to-plasma concentration ratio 
values of phenobarbital, clobazam, zonisamide, gabapentin, 
tiagabine, and levetiracetam were higher in  mdr1a/b/
Bcrp  triple knockout mice than those in  mdr1a/b  double 
knockout mice, suggesting the involvement of BCRP in the 
transport of these AEDs. 
Current evidence suggests that most AEDs are not 
transported by BCRP, though discrepancies exist between in 
vitro and in vivo findings [49].
Efflux Transporter Upregulation Mechanism in Epilepsy. 
An important question that stems from the transporter 
hypothesis is whether overexpression of efflux transporters 
at the blood-brain barrier observed in epilepsy is acquired 
or constitutive. Current evidence suggests that seizures, 
genetic factors, or a combination of both are likely to be the 
major contributors to efflux transporter overexpression at 
the blood-brain barrier in epilepsy [31]. Experimental data 
mostly from animal studies support that P-gp upregulation 
in epileptic regions of the brain occurs mainly as a result of 
seizure activity. Van Vliet et al. [50] also reported increased 
MRP1, MRP2, and BCRP protein expression levels in rat 
astrocytes and cerebral blood vessels after acute status 
epilepticus and in chronic epilepsy. Similar to the finding 
with P-gp, overexpression of these transporters was greater 
in chronic epileptic rats that demonstrated progression of 
epilepsy. 
Recent research in the field has postulated two main 
mechanisms leading to efflux transporter overexpression in 
the brain in epilepsy: (1) AED-mediated induction of efflux 
transporters via nuclear receptors and (2) seizure-induced 
signaling causing efflux transporter overexpression [31]. 
Regarding the first mechanism, studies on whether AEDs 
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induce efflux transporter overexpression have yielded 
inconsistent results. However, studies have shown that 
seizures induce brain capillary P-gp expression levels.  If 
P-gp levels were already maximally induced in the study of 
Wang-Tilz et al. [51], one would not expect to see additional 
increases in P-gp expression levels by AEDs. Consistent 
with this, Wen et al. reported due to AED activation of the 
ligand-activated transcription factors pregnant X receptor 
and/or constitutive androstane receptor [52]. It is important 
to note that AED-mediated upregulation of drug efflux 
transporters at the blood-brain barrier and in other tissues 
does not explain why some patients are resistant to the 
very first AED they are given. While this speaks against the 
theory that AEDs are the main cause for drug resistance due 
to transporter upregulation, it is possible that AEDs are one 
contributor, among others, to refractory epilepsy [31]. 
The second mechanism that has been shown to result 
in increased efflux transporter expression levels is through 
recurring seizures. In this regard, Lazarowski et al. [53] 
showed that daily induced seizures result in a progressive 
increase of P-gp protein expression at the blood-brain barrier, 
and further will cause resistance. Importantly, resistance to 
drugs that are not P-gp substrates, such as carbamazepine, 
diazepam, or levetiracetam was not observed. Therefore, this 
new model could be useful for screening novel AEDs that 
are P-gp substrates and have the potential to control seizures 
in pharmacoresistant epilepsy.
The molecular signaling mechanism underlying in-
creased efflux transporter expression levels in epilepsy has 
been studied. In this regard, evidence from in vitro and in 
vivo rodent studies suggests that targeting this pathway could 
control P-gp expression and activity levels, and thus, help 
increase AED brain penetration and improve AED efficacy 
to control seizures in drug-resistant epilepsy. To fully as-
sess if P-gp upregulation has any relevant consequences on 
pharmacoresistance, studying P-gp expression in brain tissue 
from both AED-responsive and AED-resistant patients and/
or conducting PET imaging using P-gp substrates or inhibi-
tors in patients would be critical. At present, aspects of the 
transporter hypothesis are still controversial, and further re-
search is needed to determine the clinical relevance of efflux 
transporter overexpression at the blood-brain barrier [31].
Pharmacokinetic hypothesis. The pharmacokinetic hy-
pothesis proposes that overexpression of efflux transport-
ers in peripheral organs, such as intestine, liver, and kidney 
decreases ASD plasma levels in refractory epilepsy patients, 
thereby reducing the amount of ASD available to cross the 
blood-brain barrier and reach the epileptic focus in the brain 
[54].
Alterations in expression and functionality of multidrug 
transporters in patients with intractable epilepsy need not 
necessarily be restricted to the brain but could also occur in 
other tissues, such as the small intestine, where P-glycopro-
tein is thought to form a barrier against entrance of drugs 
from the intestinal lumen into the bloodstream, thereby 
limiting their oral bioavailability. In support of this theory, 
several studies have reported persistent subtherapeutic plas-
ma levels of anticonvulsants (including phenytoin and phe-
nobarbital) despite aggressive and chronic administration 
of anticonvulsants in patients with drug-resistant epilepsy 
that has been associated with overexpression of MDR1 [32]. 
Support for the pharmacokinetic hypothesis comes from 
studies showing persistently low ASD levels in patients with 
drug-resistant epilepsy, which, however, relate to drug me-
tabolizing enzymes rather than to efflux transporters such as 
P-glycoprotein [31]. The metabolism of ASDs is mainly me-
diated by liver cytochrome P450. Some of the cytochromes 
of this group have allelic types encoding isoforms which 
have different activity and, in turn, can affect the concen-
tration of many drugs, including ASDs, in the blood serum. 
Cytochrome P450 metabolic enzymes not only occur in the 
periphery, but also in the brain parenchyma and endothe-
lial cells of the blood-brain barrier, thus adding to the bar-
rier function. Changes in the cerebrovascular hemodynamic 
conditions can affect expression of cytochrome P450 en-
zymes and multidrug-resistance transporters, leading to a 
synergistic role in drug resistance [55].
The liver is involved in potential pharmacokinetic 
changes by overexpression of P-gp, 99mTc-hexakis-2-me-
thoxyisobutylisonitrile, what increased hepatic clearance 
that could contribute to ASD resistance [56]. The animal 
studies do not support the pharmacokinetic hypothesis 
[27]. In addition, data from clinical studies show that ASD-
responsive and ASD-resistant patients display adverse 
events to the same extent, suggesting similar plasma ASD 
levels in the two groups of patients [32]. One explanation 
for this observation is that efflux transporter overexpression 
is restricted to the epileptic focus. This observation also 
suggests that the same plasma ASD concentrations are due 
to the same enzyme and transporter expression levels in pe-
ripheral organs. While both explanations are plausible, one 
does not necessarily lead to the other.
Together, the pharmacokinetic hypothesis of refractory 
epilepsy as a stand-alone theory is difficult to validate. 
One can argue that because abnormalities in ASD plasma 
concentrations can be readily captured by therapeutic drug 
monitoring, pharmacokinetic variability is probably not 
a major contributor to pharmacoresistance in situations 
where ASD doses are adjusted accordingly. This argument, 
however, is further complicated because therapeutic ASD 
plasma concentrations vary among patients, and no one 
specific therapeutic ASD concentration range is applicable 
to all patients.
Neural network hypothesis. Growing body of electrophys-
iological, neuroimaging, and clinical evidence suggests that 
epilepsy, including drug-resistant epilepsy, is a network dis-
order. Recent observations led to the emergence of the neural 
network hypothesis that might mechanistically explain the 
development of drug-resistant epilepsy [31]. According to 
this hypothesis, epilepsy-associated structural and function-
al alterations lead to an abnormal and maladaptive remodel-
ling of neural networks that become resistant to antiepileptic 
medication. The underlying substrates of a maladaptive net-
work architecture range from axonal sprouting and synaptic 
77
ReVIeW ARTIcLe V. Chiosa et al. Moldovan Medical Journal. October 2021;64(4):72-85
 
reorganization to neurogenesis and gliosis [31]. Structural 
alterations in both drug-resistant lesional and non-lesional 
epilepsy are widespread and extend to regions beyond the 
borders of the epileptogenic focus. Thus, patients with tem-
poral lobe epilepsy show significantly reduced cortical thick-
ness in the supramarginal, middle and upper temporal gyri, 
temporal pole, insula, cuneus, superior frontal, precentral, 
posterior cingulate, operculum, lateral orbitofrontal, lingual, 
upper parietal, postcentral, lower parietal, lateral occipital, 
paracentral and isthmus cingulate of the right hemisphere 
[57]. In the left hemisphere, cortical thinning was identi-
fied in the supramarginal, precentral, and middle frontal re-
gions. Like structural connectivity, functional connectivity 
displays distinct and frequency-dependent changes in the 
interregional neural oscillations. Thus, in theta frequency, 
connectivity from the temporal and frontal lobes to thala-
mus initially shows a continuous decrease in the connectiv-
ity intensity, later followed by a continuous increase before 
the spike generation [57]. In contrast, connectivity from the 
thalamus to the frontal lobe shows an inverted pattern – ini-
tial continuous increase in connectivity intensity, followed 
by a decrease in connectivity [57]. Several factors modulat-
ing the topology of neural networks in patients with drug-
resistant epilepsy have been described. Thus, patients with 
sleep- and awake-related seizures display different patterns 
of structural alterations and network organization. Patients 
with sleep-related seizures compared to those with awake-
related seizures have larger volumes of bilateral insula, su-
perior temporal, and orbitofrontal cortices [58]. Volumes of 
hippocampus, amygdala, caudate, pallidum, and putamen 
are larger in patients with sleep-related seizures than in pa-
tients with awake-related seizures [58].
Summing up, patterns of brain network reorganization 
in drug-resistant epilepsy are characterized by an increased 
segregability, low integrability, and reduced resilience [59]. 
However, one of the substantial limitations of this hypothesis 
is that neural network alterations lead to treatment 
refractoriness not in all epilepsy patients, and therefore, 
further studies are required to establish the clear-cut network 
alterations related to drug resistance.
The gene variant hypothesis. In recent years, numerous 
studies have demonstrated that genetic variation is involved 
in the drug resistance of epilepsy [60]. Gene variants in 
transporters, targets as well as metabolizing enzymes, are 
hypothesized to contribute to drug resistance mechanisms, 
especially genetic variations found in drug resistance-related 
genes, including the voltage-dependent sodium and potassi-
um channels genes, and the metabolizer of endogenous and 
xenobiotic substances genes. Advances in genomic technolo-
gies have facilitated the genome-wide discovery of common 
and rare variants and have increased our understanding of 
genetics in epilepsy; however, the mechanisms underlying 
pharmacological resistance have not been fully elucidated. 
The most frequently studied polymorphisms are those asso-
ciated with multidrug resistance genes (MDR): ATP-bind-
ing cassette subfamily B member 1 (ABCB1 or MDR1) and 
ATP-binding cassette subfamily C member 2 (ABCC2 or 
MRP2); SCN α subunits 1, 2 and 3 (SCN1, SCN2 and SCN3); 
and metabolizers of endogenous and xenobiotic substances, 
cytochromes P450 families 2 and 3 (CYP2 and CYP3) [61]. 
For example, a meta-analysis on the ABCB1 C3435T poly-
morphism showed association of CC genotype with drug-
resistant epilepsy in Caucasians only, while a more recent 
systematic review showed the TT genotype polymorphism 
to be correlated [62]. Also, in intractable epilepsy and other 
mental disabilities, whole-exome sequencing (WES) iden-
tified de novo variants in the Bernardinelli-Seip congenital 
lipodystrophy 2 (BSCL2) gene in two patients [63], or the 
case of recently reported changes in the KCNQ2 gene which 
present with both benign seizure disorders and early onset 
epileptic encephalopathies (EOEE), the latter including pa-
tients who present refractory seizures following standard 
AED treatment and development delay [64]. 
It is hypothesized that genetic variants may also contribute 
to the efficacy of drug treatments for epilepsy; for example, 
adverse or toxic reactions, teratogenic risk in pregnancy, 
as well as long-term outcomes have been observed among 
PWE [65]. In recent studies, the association between genetic 
polymorphisms, treatment responses in epilepsy and 
antiepileptic drugs (AED) reactions (toxic, adverse or those 
related with its efficacy) have been investigated.
It was reported that polymorphisms in the human leuko-
cyte antigen (HLA) gene were associated with severe cuta-
neous adverse AED reactions [66], and polymorphisms in a 
number of other genes, including ABCB1, ABCC2, GABRA6, 
GABRG2, CYP2C9, CYP3A4, UDP-glucuronosyltransferase 
(UGT)1A1, UGT1A4, UGT1A6, UGT2B7, SCN2A  and SC-
N1A, have been associated with the concentration, response 
and efficacy of some of the most commonly used AEDs in 
clinical practice, including carbamazepine, oxcarbazepine, 
phenytoin, lamotrigine and valproic acid. Esmaeilzadeh et 
al. reported an association between HLA polymorphisms 
and severe cutaneous adverse reactions (SCARs) induced 
by drugs and it was found that the hypersensitivity to dif-
ferent AEDs, including phenytoin, carbamazepine, valproic 
acid, topiramate and lamotrigine, was associated with HLA-
A  gene polymorphisms [67]. Although this hypothesis 
proposes an inherent resistance as the cause of intractable 
seizures, several underlying processes are also involved in 
epileptic seizures including microglial activation, glutamate-
induced excitotoxicity, mitochondrial dysfunction, oxidative 
stress, and the formation of reactive oxygen species [60]. Ul-
timately, this requires simultaneous malfunction of several 
enzymes, proteins, channels, and receptors [68].
Consequently, it is difficult to believe that an individual is 
born with such a vast number of gene polymorphisms to the 
extent that both pharmacokinetic and pharmacodynamic 
mechanisms are hindered. Overall drug resistant patients are 
a highly heterogeneous group and no theory in isolation can 
explain multi-drug inefficacy in every patient [69].
The epigenetic hypothesis. The genome is one source of 
endogenous variation, contributing to different disease 
risks between different people. There are, however, other 
sources of variation, such as “omes” beyond the genome: the 
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epigenome, transcriptome, proteome, microbiome, and so 
on. Some of these “omes” have been interrogated for their role 
in drug resistance in epilepsy, but it must be acknowledged 
at this point that the data available are even more sparse than 
for most genome-based studies and that, currently, none of 
these “omes” have been proven to influence drug resistance 
[27]. Studying epigenomic contribution to drug resistance 
in epilepsy [70], which is likely to be due to processes in the 
brain, is very challenging.
Epigenetic mechanisms have also been proposed to 
explain the development of pharmacoresistance in epilepsy 
patients, influencing the sustained patterns of gene expression 
that regulate AED uptake and mechanism of action. In the 
future, drugs inhibiting DNA methyltransferases (DNMTs) 
and histone lysine deacetylases (KDACs) could provide new 
treatments for patients unaffected by currently available 
anti-epilepsy medications. Not only are drugs acting on 
epigenetic processes currently available and in development 
for a variety of human diseases, but there is some evidence 
that one or more commonly used AEDs may act, in 
part, through epigenetic mechanisms. Most of the work 
identifying epigenetic changes in epilepsy has focused on 
DNA methylation. Recently, there has been exceptional 
interest in the role of microRNAs, especially where attention 
has also focused on their potential for use as biomarkers 
to support early diagnosis and prognosis in the clinic. In 
contrast, other aspects, such as histone modifications and 
long noncoding RNAs, have been less studied [71].
Among classes of molecules constituting the epigenome 
are histones and noncoding RNAs, both long and shorter, in-
cluding microRNAs. The latter contribute to RNA silencing 
and post-transcriptional regulation of gene expression, alter-
ing expression levels of multiple proteins. A central problem 
in studying the epigenome in humans is to disentangle cause 
from effect and relevance either way from epiphenomena 
[27]. The mechanisms of action of ketogenic diet in epilepsy 
have been revealed recently, such as epigenetic mechanism 
for increase the adenosine level in the brain and inhibition 
of DNA methylation. Thus, although a series of microRNAs 
have been shown to associate with human TLE [72], the 
studied tissue had been surgically resected from people with 
drug resistance, and cause and effect (for either disease sus-
ceptibility or drug resistance) could not be distinguished. In 
animal models, manipulation of specific microRNAs can in-
fluence seizures and disease [73], though some data are less 
supportive, however, whether this would be the case in hu-
man epilepsy, and specifically whether this approach would 
counter drug resistance, remains unknown.
Neuroinflammatory hypothesis. Accumulating evidence 
over the past decade indicates an important pathophysiological 
role of brain inflammation in pharmacoresistant epilepsy. 
Different inflammatory molecules and pathways have been 
shown to significantly contribute to the mechanisms of 
seizure generation and progression in different experimental 
models [74]. Inflammation refers to the complex biological 
response of tissues against infections or sterile (non-
infectious) injuries, it is closely associated with the activation 
of both innate and adaptive immune cells. It represents a 
key homeostatic mechanism of the body’s defense, which 
is crucial for activating mechanisms for tissue repair, via 
the production of a large array of inflammatory cytokines 
and related effector molecules. A novel emerging concept 
in inflammation is the specific interaction between the 
innate immune system and injured brain tissue, known as 
neuroinflammation. Although neuroinflammation currently 
lacks a consensus definition, in general it can be seen as the 
biosynthesis and release of molecules with inflammatory 
properties by resident cells of the brain, including activated 
microglia and astrocytes, neurons, endothelial cells of the 
blood-brain barrier, and blood-born macrophages. 
A notable finding is that the inflammatory mediators 
released by the resident brain cells during epileptic activ-
ity (i.e. cytokines, chemokines, alarmins/danger signals, 
prostaglandins, complement factors) are not only effectors 
molecules of the immune system promoting local inflamma-
tion, but also function as neuromodulators directly affecting 
neuronal function and excitability [75]. Prominent changes 
in several immune/inflammatory pathways, such as IL-1R1/
TLR4, COX-2, TNF-a, complement and chemokines have 
been reported within epileptogenic lesions in preclinical and 
clinical studies. These pathways seem critically involved in 
ictogenesis and epileptogenesis. A more detailed assessment 
of the use of these inflammatory pathways is needed as po-
tential biomarkers which contribute to the development of 
epilepsy or to measure the effectiveness of therapeutic in-
terventions.
Gut-brain axis. The “gut microbiota-brain axis” is the 
interaction between gut microbiome and brain. This bidi-
rectional communication is provided by the nervous, en-
docrine, immune, circulatory, and metabolic pathways [76]. 
Ketogenic Diet (KD) may be considered another alternative 
treatment in drug-resistant epilepsy (DRE). This type of diet 
was used since 1921, in the treatment of intractable epilepsy 
in children. 
Animal models. Olson et al., demonstrated in two-seizure 
mouse models, KD changes microbiota and leads to anti-sei-
zure protection. KD fed-mice have demonstrated a decreas-
ing in seizure duration and frequency. Also, it was measured 
the level of GABA and glutamate. GABA levels were higher 
in KD fed-mice. The direct association between chronic 
stress-induced epilepsy and intestinal dysbiosis in Sprague-
Dawley rats was reported in a study [77].
KD, microbiome and epilepsy. KD is a high-fat, and very 
low-carbohydrate diet. KD in children with retractable epi-
lepsy was evaluated in randomized controlled prospective 
study. Patients had a relevant decreasing in seizure severity. 
Seizures were reduced to at least 50% in children who re-
ceived KD. The effect of the KD on gut microbiome in chil-
dren with DRE, due to GLUT-1 deficiency was investigated 
for 90 days. Compared with baseline increasing in Desulfovi-
brio species was established after KD. There were no signifi-
cant differences in Bacteroidetes and Firmicutes levels. Xie et 
al., used KD (4:1 ratio) for a week. They noticed that 64% of 
children with DRE had ≥50% decreasing in seizure frequen-
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cy. Compared with baseline, while Bacteroides increased 
markedly, Bifidobacterium increased less significantly after 
KD therapy. Cronobacter, which was at high levels before 
KD, after therapy presented similar levels with the control 
group [78]. KD (4:1 ratio) was used in children (five patients 
had Dravet syndrome, three each had West syndrome and 
Lennox-Gastaut syndrome, and the remainder couldn’t be 
classified) for six months. Reduction of Firmicutes and in-
creasing Bacteroidetes levels were reported after therapy. 
KD-non-responder group demonstrated increased levels 
of Clostridiales, Ruminococcaceae, Rikenellaceae, Lachno-
spiraceae, and Alistipes, comparative with responder group 
[79]. Lindefeldt et al., evaluated the effect of KD on eleven 
children with DRE (due to perinatal asphyxia, encephalitis, 
cortical dysplasia, tuberous sclerosis, and unknown cause) 
and one with pyruvate dehydrogenase deficiency. Relative 
abundance of Escherichia coli increasing was observed on 
KD. Levels of Bifidobacteria as well as Eubacterium rectale 
and Dialister were decreased during KD therapy [80].
Gut dysbiosis in epilepsy patients. Probiotics show benefi-
cial effect on seizures in patients with DRE. In a pilot study 
was shown seizures reduction and higher quality of life in 
28.9% of adult patients with DRE, who were treated with 
probiotic cocktail [81]. Another study demonstrated that ro-
tavirus infection manifests a risk factor for neonatal seizures. 
Probiotic administration after birth was linked with reduced 
risk of seizures [82]. Peng et al, established that Bacteroide-
tes phylum is the largest one (56.7 % in Drug Sensitive (DS) 
and 57.2% in Healthy Control (HC)); Firmicutes phylum is 
the second dominant (38.2% in DS and 37.5% in HC). The 
while, Bacteroidetes was relatively lower (45.7%), and the 
Firmicutes was the largest phylum (46.9%) in patients with 
DRE. Also, it was shown an increasing of other rare phyla 
in the DRE group; Verrucomicrobia was more abundant in 
the DRE group (0.32%) than (0.03% in DS) and (0.09% in 
HC) groups. Patients with DRE have altered composition of 
gut microbiota; so, dysbiosis may be implicated in the patho-
physiology of DRE.
Biomarkers of drug-resistant epilepsy
Biomarkers may play a role in individualized epileptic 
treatment, based on the patients’ biomarker profile. Molecular 
biomarkers, inflammatory markers can indicate not only the 
presence, type, and severity of neuropathologically damaged 
tissue with epileptogenic potential, but may also have the 
potential for localizing epileptogenic zone (EZ) [83]. 
Metabolites, proteins, messenger RNAs (mRNAs) and 
microRNAs (miRNAs) play a critical role in the regulation 
of neuronal biological processes, as well they might have 
importance in early disease diagnosis, effective prognostic 
monitoring and can be clubbed with existing techniques to 
preoperatively localize the EZ. Thus, the challenge is to find 
a biomarker which one can help accurately localize the EZ 
and offering new therapeutic approach strategies. Several 
microarray and target studies have reported a differential 
expression of more than 100 miRNAs in epilepsy. From those, 
miR-146a, miR-155 and miR-132 have a key role in epilepsy-
related biological processes, such as neuroinflammation, 
neuronal growth, neuroprotection and neurodegeneration 
[84]. MiRNA-155 has been shown, in experimental studies, 
to be much higher in patients with generalized genetic 
epilepsy compared to control, and miRNA-4521 could serve 
as a potential biomarker in refractory epilepsy. Changes 
in the mRNA levels of various  glutamate  and  gamma-
aminobutyric acid (GABA)  receptor subunits modulating 
of glutamatergic and GABAergic synaptic transmission, also 
mRNA polyadenylation profile can be utilized as a biomarker 
in generalized, and focal epilepsies [85]. Inflammatory 
molecules have been identified in experimental models of 
epilepsy and surgically resected brain tissue from treatment-
resistant epilepsy. Different components especially, 
cyclooxygenase-2 (COX-2) play an important role in the post 
seizure inflammation, possibly contributing to secondary 
damage in the brain and the increased likelihood of repetitive 
seizures. High mobility group box-1 (HMGB1), that takes 
part in the immune response via activating macrophages 
and endothelial cells, leading to the release of tumor necrosis 
factor-a (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6) 
has been indicated as a potential therapeutic agent in epilepsy 
and as a non-invasive biomarker, which could identify 
patients with high risk of epilepsy. The level of HMGB1 
has been shown to increase within 3–4 h after seizure, 
proving HMGB1 to be a promising marker. Moreover, it is 
known that in drug-resistant epilepsy (DRE) resulting from 
Rasmussen’s encephalitis, some patients showed seizure 
improvement following adalimumab administration, an 
anti-TNF-a therapy [86]. 
 In sum, biomarker discovery and validation efforts need 
to balance between curation and control on the one hand, 
while allowing for broader coverage and generalizability on 
the other [87].  In time, this will lead to the development of 
effective strategies for the early screening, clinical diagnosis, 
treatment, and prevention of refractory epilepsy.
Advances in pharmacological treatment
Several antiepileptic drugs are currently in clinical trials 
whose mode of action is either historical, novel or adapted 
from previous AEDs. Everolimus, a compound which had 
been in use primarily for other clinical indications (renal 
cancer, organ transplant immunosuppression, metastatic 
neuroendocrine tumors) was approved in 2018 and has 
shown promise as an antiepileptogenic agent in patients with 
tuberous sclerosis. It works as an inhibitor of an overactive 
and dysregulated mTOR pathway. EXIST-3 trial [88] showed 
response rate of 28.2% and 40.0% for low-exposure and high-
exposure everolimus, respectively, compared to placebo of 
15.1%. Other compounds already in use for other medical 
indications and being tested in epilepsy include melatonin, 
biperiden, fenfluramine, bumetanide and verapamil [89]. 
Apart from these clinical in-use medications, drugs specifi-
cally designed for epilepsy are under investigation. 
Clinical studies of cenobamate, which was recently ap-
proved for the treatment of partial-onset seizures in adults, 
showed approximately 20% of patients experienced seizure 
freedom, which is very impressive compared with previous 
add-on clinical trials with various other novel AEDs in pa-
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tients with DRE [90]. A similar impressive antiseizure effect 
has been observed with the novel ASD fenfluramine in Dra-
vet syndrome, in which approximately 25% of patients had 
long-term seizure freedom, suggesting that the long hoped-
for breakthrough is a feasible goal [91].
Other compounds undergoing recruitment in phase 2/3 
studies (registered on Clinicaltrials.gov) include padsevonil, 
neurosteroids (ganoxolone), XEN1101, E2082 and vori-
nostat. Several other drugs appear to be suspended due to 
failed early stage efficacy studies and others will need further 
preliminary data to assess their potential [89]. Cannabidiol 
studies have had a surge of interest after successes in recent 
trials of patients with Dravet and Lennox-Gastaut (LGS) 
syndromes and further open-label study has shown good re-
tention rate, efficacy and safety data [92].
Epidiolex is the first canabidiol oral solution to be FDA 
(Food and Drug Administration)  approved. Double-blind 
controlled studies showed significant seizure reduction in 
the range of 17%–23% compared to placebo for monthly 
convulsive seizures in Dravet syndrome and monthly total 
seizure reduction in the two pivotal LGS trials [93]. Overall, 
most of the drugs in the pipeline have similar mechanism 
of actions to traditional drugs. Clinical benefits over exist-
ing drugs are, therefore, unlikely in the near future. Along-
side the novelty in drug therapy explored by pharmaceutical 
companies, viral-vector mediated gene therapy has demon-
strated success in animal models of focal neocortical epilep-
sy using chemical-genetics and optogenetics, but no human 
trials are yet in progress.
Gene therapy. The use of novel therapeutic approaches in 
the management of epilepsy is steadily progressing. Neuro-
logical disorders are sometimes caused by inherited or ac-
quired genetic changes that lead to abnormal nervous sys-
tem development, neurodegeneration, or impaired neuronal 
function. About 30% of the epilepsies have been thought to 
have a genetic origin [94]. Gene therapy, as an emerging and 
novel therapeutic approach has curative potentials of the 
most common neurological disorders including DRE. It had 
been formerly defined as a method to replace the defective 
copy of a gene with a normal copy which acts correctly in 
the cells [95]. There are various methods to transfer and ex-
press a gene in a particular region of the brain that include 
cell transplantation, liposomes, non-viral and viral vector 
delivery, (adenovirus, adeno-associated virus, herpes sim-
plex virus, lentivirus, and retrovirus). Gene therapy for DRE 
treatment aims to induce the local release of anticonvulsant 
or antiepileptogenic properties to counterbalance between 
excitation and inhibition in the brain. It offers the possibility 
of targeting therapeutic genes expressing in the seizure gen-
erating area without needing tissue ablation. These results 
are very promising; however, it is important to note that only 
infrequent types of epilepsy are caused by a single mutant 
gene; while they are commonly caused by inheritance of two 
or more susceptibility genes that usually influence a large part 
of the brain. Therefore, an extensive gene transfer is needed; 
however, the presently available gene therapies provide only 
local effects [94]. Improvement in the gene therapy-treating 
epilepsy can be possible through progress in understand-
ing the disease mechanisms, designing suitable gene vec-
tors, selecting suitable genes, and choosing the right delivery 
methods. Taken together, gene therapy can be considered 
as a therapeutic approach in the management of epilepsy; 
but further studies are needed to verify the safety and effi-
cacy of this method in human. Gene therapy is a more chal-
lenging and complicated process than the simple concept of 
gene replacement. Techniques for transferring of exogenous 
genes into the desired sequence of target cells have been re-
markably improved. Clustered regularly interspaced short 
palindromic repeats (CRISPR) are types of nucleic acid se-
quences that function in harmony with CRISPR-associated 
(Cas) proteins to provide immunity in bacteria and archaea 
against foreign invasion of nucleotides, such as viruses, plas-
mid, and phages. CRISPR-Cas9 system has recently attracted 
increasing attention for therapeutic applications [96]. This 
system has presented a novel approach in repairing gene de-
fects for treating various types of disorders including neuro-
logical diseases. Due to its potential in targeted gene editing 
and repairing of genetic mutations, CRISPR-Cas9 can also 
be considered for applying as a possible therapeutic ap-
proach in treating DRE with genetic origins. Although it is 
the most powerful and useful technique for the multiplexed 
genome manipulating, there are still some challenges regard-
ing efficiency and accuracy concerns, and further studies are 
needed to verify its safety before clinical applications. Sev-
eral studies with the aim of epilepsy treating have applied 
various cell types, such as neural stem cells, mesenchymal 
stem cells, hippocampal precursor cells, GABAergic precur-
sor cells, and bone marrow-derived mononuclear cells. They 
all aim to diminish seizure severity and frequency in the 
brain through different mechanisms of action. Although the 
results are encouraging, to use cell therapy in clinical appli-
cation, additional and vigorous studies are necessary to test 
safety and efficacy of this approach [97].
Exosome therapy. The exosome is a kind of extracel-
lular vesicles which have initially been recognized in the 
1980s. Exosomes are characterized by homogeneous shaped 
nano (40–100  nm) membranous vesicles with a density of 
1.13–1.19 g/cm2. They can be secreted by several body cell 
types and have been detected in the various biological flu-
ids including blood, urine, saliva, CSF, breast milk, amniotic 
fluid, malignant ascites, bronchoalveolar fluid, and synovial 
fluid. Depending on their source cells, exosomes can contain 
a variety of lipids, proteins, and genetic elements, such as 
DNA, non-coding RNAs, mRNAs, and microRNAs. These 
agents which are also known as “cargo” can be delivered to 
the surrounding cells or transferred to other distal cells and 
alter the recipient cell function. Therefore, exosomes can 
be considered as a novel form of intercellular communica-
tion. Interestingly, it has been shown that many cells of the 
nervous system, such as neurons, microglia, astrocytes, oli-
godendrocytes, and neural stem cells can release exosomes. 
Thus, exosomes may have a role in the function, develop-
ment, and pathologies of the nervous system [98]. Emerg-
ing pieces of evidence have suggested that exosomes can be 
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used to rescue neuronal pathologies and alterations. It has 
been revealed that these vesicles have crucial roles in the re-
generation process and repair of the nervous system. Their 
simple structure, low immunogenicity, and ability to cross 
the blood-brain barrier (BBB) have made a great opportu-
nity to engineer and apply them as vehicles for delivering 
microRNAs, drugs, proteins, and other active agents to the 
brain. MicroRNAs have been known as master regulators of 
gene expression. In the nervous system, they can alter the 
regulation of various proteins which associate with several 
neuronal processes and actions. They have been shown to 
regulate essential genes involved in seizure susceptibility. 
Therefore, exosomes contained the agents which have anti-
seizure activity can be potentially applied to manage and 
treat epilepsy. However, more studies are needed to address 
their use in clinical trials [84, 98].
neuromodulation in pharmacoresistant epilepsy
Correctly selected antiepileptic drugs (AEDs) show good 
clinical improvement in most individuals with epilepsy, al-
though almost a third of these patients at some point will 
present an inadequate or insufficient response to current 
AEDs [99]. In individuals with drug-resistant epilepsy the 
percentage of general morbidity and mortality is significant-
ly higher when compared to drug responsive cases. There-
fore, there is a consistent need for improving therapeutically 
management in this population. From a pathophysiological 
point of view, epilepsy is a result of abnormal neuronal net-
work activity in the brain due to a pathological increase in 
excitatory synapses (Glutaminergic) with a decrease in in-
hibitory activity (GABA-ergic). Thus, approaching this para-
digm it is assumed that inhibitory neuromodulation could 
induce the phenomenon of LTD (long-term excitatory de-
pression) with normalization of the excitation threshold in 
hyperactive areas and as a result obtain the expected thera-
peutic effect. Modulation of brain activity can be achieved by 
impacting specific intra/ extracranial targets, either the pe-
ripheral elements of sensitization or direct cortical-subcor-
tical activity as shown in Figure 1. By influencing the activ-
ity of these components, a modulation of either widespread 
brain networks or direct modulation of network nodes can 
be achieved.
Vagal nerve stimulation (VNS) involves intermittent 
electrical stimulation of the afferent fibers of the left cervical 
vagus nerve in a transcutaneous (tVNS) or non-invasive 
(nVNS) way or by means of an implanted helical electrode 
connected to a pulse generator. The therapeutic efficacy 
of VNS appears to be mediated by the activation of fast 
myelinated fibers in the vagus nerve. Its anticonvulsant 
effect can be explained by several mechanisms, such as the 
modulation of neurotransmitter expression with increased 
inhibition and reduced excitability, changes in cerebral 
blood flow, desynchronization of electroencephalographic 
(EEG) rhythms, and anti-inflammatory effects mediated by 
norepinephrine [100].
Transcranial direct current stimulation (tDCS) is a non-
invasive method that modulates cortical excitability using 
a weak constant electric current passing through two elec-
trodes (anode and cathode) applied over the skull. Cortical 
excitability may increase following anodal stimulation, while 
it generally decreases after cathodal stimulation. Consider-
ing this principle, hyperpolarization using cathodal tDCS 
has been proposed as therapy to suppress epileptiform dis-
charges [101]. 
Trigeminal nerve stimulation (TNS) similar to VNS and 
tDCS uses electrical stimuli but targets trigeminal sensory 
roots within the facial tissue (ophthalmic nerve, supra-
trochlear nerve, infraorbital nerve). Considering the projec-
tions of the trigeminal pathway, it is thought to generate an 
arousal-like effect from stimulation of the reticular activat-
ing system which leads to a shift of cortical activity from a 
“synchronized” state to a “desynchronized” state. As seizures 
present highly synchronous activity, it was hypothesized that 
desynchronization of the neocortex would have an anticon-
vulsant effect [102].
Transcranial magnetic stimulation (TMS) is a non-invasive 
brain stimulation technique which using electromagnetic 
induction phenomenon is able to module electrical activity 
of targeted cortical areas. The application of low-frequency 
(<1Hz) repetitive TMS or continuous theta burst stimulation 
(cTBS) modulates the cortical excitability and produces 
its relatively long-term depression-like mechanisms in the 
cortex [103].
Deep brain stimulation (DBS) is an invasive neuromodu-
lation technique that uses electrical stimulation through 
electrode implantation within the anterior nucleus of thala-
mus, centromedian nucleus of thalamus, cerebellum, hip-
pocampus, or subthalamic nucleus to interfere with neuro-
nal synchronized oscillations, thus inducing modulation of 
pathological neural networks [104].
Responsive neurostimulation (RNS) is a closed loop, inva-
sive brain stimulation method that aims to suppress ictal ac-
tivity by delivering stimulation directly in response to elec-
trographic activity; it is highly time- and area-specific, there-
fore providing stimulation only when needed [100] (fig. 1).
By reducing cortical excitability, targeted neuromodula-
tion has enormous therapeutic potential in the treatment of 
epilepsy, especially in drug-resistant epilepsy.
Perspectives
The issue of drug resistance to epilepsy remains relevant 
to date. Thus, the use of an integrated approach, personalizing 
the therapy of patients with refractory epilepsy, can achieve 
significant positive results.
Therefore, a therapeutic strategy for drug-resistant 
epilepsy should be based on the one hand, on the suppression 
of epileptogenesis and, on the other hand, on overcoming 
drug resistance. An integrated approach to the problem of 
drug resistance will allow not only obtaining new data on 
the mechanisms of the pathogenesis of epilepsy, but also 
improving the algorithm for treating patients and increasing 
its effectiveness.
Although the previous decades have noted remarkable 
developments in the neurosciences, technological improve-
ments in diagnostics (genetics, imaging, electrophysiology) 
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and increased options of drug therapies, epidemiological 
studies suggest that this has not translated in wide benefits 
for drug-resistant patients [105].
Conclusions
Neuroscience of drug-resistant epilepsy faces many chal-
lenges. Inflammatory mediators, biomarkers, and genes 
might allow the identification of new treatment targets, 
contribute to an earlier diagnosis, and assess the clinical 
outcomes. New therapeutic approaches, with personalized 
therapy for each patient, offer better perspectives for patients 
and their families. Thus, drug resistance in epilepsy is an ur-
gent scientific and practical issue that requires fundamental 
and interdependent clinical research. The further develop-
ment of new surgical methods and non-surgical treatment 
of drug-resistant epilepsy remains relevant, including the 
modernization of neurorehabilitation methods.
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